DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings



    Ticker Symbol: CUR

    QUEBEC CITY, June 3 /CNW Telbec/ - Two of DiagnoCure Inc. (TSX: CUR)
products, the PCA3 marker for the detection of prostate cancer and GCC for the
staging of colorectal cancer, were discussed at recent scientific meetings as
part of the growing trend to molecular diagnostics.
    Yesterday, on June 2nd, DiagnoCure opened the sessions at the 34th Annual
International Clinical Ligand Assay Society Meeting, held in Coral Springs,
Florida, with a presentation on its guanylyl cyclase C (GCC) testing research.
    Timothy J. Holzer, Ph.D., Vice President, R&D and Production at
DiagnoCure, presented research data on "Molecular Detection of Colorectal
Cancer Lymph Node Micrometastasis". Dr. Holzer's presentation featured a
statistical review and discussion of the beneficial role of GCC in the staging
of colorectal cancer.
    GCC is expressed only in intestinal mucosal cells, but not in
extra-intestinal tissues. In addition, GCC is expressed in colorectal tumors,
but not in other cancers outside the gastro-intestinal tract. Therefore, GCC
may be useful clinically for the management of patients with colorectal cancer
in providing more accurate information to physicians and patients and
influencing treatment decisions.
    In a review of a prototype colorectal cancer staging test in its Quebec
facility utilizing nearly 1,500 lymph nodes, a DiagnoCure's study demonstrated
that in patients previously staged as having no positive lymph nodes
(Stage II), 30 percent had at least one lymph node with GCC expression at
least as high as that found in lymph nodes called positive by a pathologist
(Stage III). This would indicate that these patients should be considered for
cancer management equal to that for a Stage III patient.
    During the same event, the PCA3-based test was also featured in a
presentation by Ina Deras, Ph.D., Senior Research Scientist at Gen-Probe Inc.,
titled "PCA3 as a Biomarker for Prostate Cancer Disease Stratification".
    At the American Society of Clinical Oncology (ASCO) annual meeting in
Chicago, which is ending today, DiagnoCure is introducing Previstage(TM) GCC,
a molecular diagnostic solution for the need to more accurate staging of
colorectal cancer, to the medical community. Attending key opinion leaders
from the colorectal cancer treatment community expressed great interest in
DiagnoCure's Previstage(TM) GCC test. The ASCO meeting is host to over
30,000 health practitioners concerned with cancer.
    At the meeting of the American Urological Association (AUA) in Orlando,
Florida, the PCA3 marker-based test was the subject of several presentations
and three exhibits. The meeting was at ended by over 10,000 urologists from
around the world. Gen-Probe Incorporated, DiagnoCure's commercialization
partner for PCA3, featured the test in its exhibition booth, and Dianon
(LabCorp) and AmeriPath (Quest) had their versions of the test prominently
featured as well.
    During this key annual meeting, Dr. Yves Fradet, Founder and Chief
Medical Officer of DiagnoCure, participated in a panel of three researchers
who discussed their investigations on "The Evolution of Markers for Urologic
Cancer". Dr. Fradet presented the promising latest clinical findings on PCA3
to an audience of approximately 1,000 people. The discussion was led by
Dr. Peter T. Scardino who spoke highly of the PCA3 marker in an AUA Daily News
article.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. In addition to its own research, the Company
intends to acquire or in-license additional promising cancer biomarkers from
both academic and commercial institutions. For more information, visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF




For further information:

For further information: DiagnoCure Inc.: JF Bureau, Chief Financial
Officer, (418) 527-6100, communications@diagnocure.com; Media: U.S.: Troy
Pearson, Mentus Life Science, (858) 455-5500 X320, Troy@mentus.com; Canada:
Jean-Pierre Trudel, Jean-Pierre Trudel & Associates, (514) 347-6111,
jp.trudel@videotron.ca

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890